Bio Developments

Pic:getty/andrewbrookes

Janssen discontinues Phase 3 HIV vaccine trial

By Rachel Arthur

Janssen’s experimental HIV vaccine regimen was found to be safe but ineffective in the Phase 3 Mosaico clinical trial: and as a result the company is discontinuing the study.

Pic:getty/adamgault

Moderna to acquire OriCiro Genomics

By Rachel Arthur

mRNA specialist Moderna will acquire OriCiro Genomics K.K, a pioneer in cell-free DNA synthesis and amplification technologies, for $85m.

pic:getty/remotevtx

ExPLoRNA Therapeutics receives funding to advance mRNA tech

By Rachel Arthur

ExPLoRNA Therapeutics, a Polish biotech developing mRNA vaccines and therapeutics with improved translational efficiency, has received funding from the Bill & Melinda Gates Foundation to further develop its mRNA technology.

Pic:getty/stanislawpytel

Emmes launches cell and gene therapy center

By Rachel Arthur

Emmes has announced the creation of a dedicated center for cell and gene therapy research: which will focus on supporting clinical trials for the Clinical Research Organization’s (CRO) clients.

© GettyImages/Frank Brennan

ADDF: Anti-amyloids are a promising starting point

By Jane Byrne

The phase 3 trial results for lecanemab and gantenerumab presented at the Clinical Trials on Alzheimer’s Disease (CTAD) conference demonstrate why optimal treatment of Alzheimer’s will require drugs that do more than clear amyloid plaques, says the Alzheimer’s...

Pic:getty/kojofeja

BigHat Biosciences enters AI research collaboration with Merck

By Rachel Arthur

BigHat Biosciences, a US biotech with a machine learning-guided antibody discovery and development platform, has announced a collaboration with Merck to apply its technology to design candidates for up to three drug discovery programs.

Pic:getty/morsaimages

Blue Water Vaccines to develop oral chlamydia vaccine

By Rachel Arthur

Blue Water Vaccines has signed an exclusive, global license agreement for the development of a live attenuated, oral Chlamydia vaccine candidate from The University of Texas Health San Antonio.

Pic:getty/dzmitrydzemidovich

Long-COVID personalized medicine enters Phase 2 trial

By Rachel Arthur

GeNeuro has recruited the first patients in a Phase 2 trial evaluating temelimab against long-COVID: assessing the efficacy of the treatment for improving cognitive impairment and fatigue.

Pic:getty/nicholasfree

EdiGene Biotechnology moves into new R&D center in Massachusetts

By Rachel Arthur

EdiGene Biotechnology USA has moved into a new Research & Development Center in Waltham, Mass. to advance its proprietary LEAPER tech into in vivo RNA editing therapies: with an initial focus on ophthalmology and the central nervous system.

© GettyImages/PM Images

Most popular stories in October 2022

By Jane Byrne

Novo Nordisk, Sanofi, AstraZenec, Merck and Moderna, among others, feature in our round-up of top hitting stories last month.